Roivant Sciences Ltd.
ROIV
$36.36
$0.060.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -189.84M | 302.99M | -265.89M | -113.52M | -223.36M |
| Total Depreciation and Amortization | 600.00K | 638.00K | 691.00K | 921.00K | 1.10M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -48.57M | 133.63M | 59.34M | -80.14M | 55.04M |
| Change in Net Operating Assets | -32.70M | -601.08M | 9.37M | 7.08M | -37.17M |
| Cash from Operations | -270.50M | -163.82M | -196.48M | -185.66M | -204.38M |
| Capital Expenditure | -419.00K | -1.26M | 4.94M | -7.85M | -4.04M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -4.42M | -- | -- | -- |
| Other Investing Activities | 281.68M | 179.17M | 104.54M | 128.27M | -1.08B |
| Cash from Investing | 281.26M | 173.49M | 109.47M | 120.42M | -1.09B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 76.65M | 51.19M | 119.20M | 69.07M | 30.06M |
| Repurchase of Common Stock | -258.16M | -118.56M | -23.86M | -6.48M | -217.83M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -1.40M | 232.86M | -- | -- |
| Cash from Financing | -181.51M | -68.78M | 328.19M | 62.59M | -187.77M |
| Foreign Exchange rate Adjustments | 315.00K | 1.32M | 430.00K | 1.21M | 815.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -170.44M | -57.79M | 241.61M | -1.45M | -1.48B |